CTLA4


Also found in: Medical.
AcronymDefinition
CTLA4Cytotoxic T-Lymphocyte Antigen 4
CTLA4Cytotoxic T-Lymphocyte-Associated Protein 4 (gene)
References in periodicals archive ?
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.
In addition to many SNPs in genes such as CTLA4, PD1 and ERAP1, recent studies have shown that there is a strong association between few intragenic SNPs and AS in different populations.
The immune checkpoints inhibit the T cells at different phases of the immune response: the CTLA4 checkpoint is active in the T-cell activation phase in the lymph nodes (early or priming phase), whereas PD-1/PD-L1/PD-L2 regulate T-cell activity during the effector phase in tissues (Figure 1, B).
Also, a few molecules that may initiate the connection, such as GAD, GLIS3, and CTLA4, were explored.
DiNardo et al., "Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents," Leukemia, vol.
Petzl-Erler, "Polymorphism of the promoter region and exon 1 of the CTLA4 gene in endemic pemphigus foliaceus (fogo selvagem)," Brazilian Journal of Medical and Biological Research, vol.
8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder.
Other checkpoint inhibitor drugs that will be in focus at ASCO include those that target the CTLA4 protein, such as Bristol's Yervoy, and those that target IDO1.
(7-9) This mechanism is believed to potentiate immunomodulatory effects of checkpoint inhibitors nivolumab and ipilimumab (inhibitor of cytotoxic T-lymphocyte-associated protein, CTLA4).
[sup][74] reported that the combination therapy of RG7787 immunotoxin with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibody (an immune checkpoint inhibitor) led to a high rate of complete remissions in their breast cancer model, indicating that the combinatorial therapy of immunotoxin and immune checkpoint inhibitors may promote the activation of the antitumor immunity to achieve a long-term tumor elimination.
Now Sharma drives a Tesla with a vanity plate that reads "ICOS." On Allison's Porsche, the plate says "CTLA4."
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.